-
Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
Authors:
Mourad Tighiouart,
José L. Jiménez,
Marcio A. Diniz,
André Rogatko
Abstract:
In parametric Bayesian designs of early phase cancer clinical trials with drug combinations exploring a discrete set of partially ordered doses, several authors claimed that there is no added value in including an interaction term to model synergism between the two drugs. In this paper, we investigate these claims in the setting of continuous dose levels of the two agents. Parametric models will b…
▽ More
In parametric Bayesian designs of early phase cancer clinical trials with drug combinations exploring a discrete set of partially ordered doses, several authors claimed that there is no added value in including an interaction term to model synergism between the two drugs. In this paper, we investigate these claims in the setting of continuous dose levels of the two agents. Parametric models will be used to describe the relationship between the doses of the two agents and the probability of dose limiting toxicity and efficacy. Trial design proceeds by treating cohorts of two patients simultaneously receiving different dose combinations and response adaptive randomization. We compare trial safety and efficiency of the estimated maximum tolerated dose (MTD) curve between models that include an interaction term with models without the synergism parameter with extensive simulations. Under a selected class of dose-toxicity models and dose escalation algorithm, we found that not including an interaction term in the model can compromise the safety of the trial and reduce the pointwise reliability of the estimated MTD curve.
△ Less
Submitted 11 August, 2022;
originally announced August 2022.
-
Evaluating U-net Brain Extraction for Multi-site and Longitudinal Preclinical Stroke Imaging
Authors:
Erendiz Tarakci,
Joseph Mandeville,
Fahmeed Hyder,
Basavaraju G. Sanganahalli,
Daniel R. Thedens,
Ali Arbab,
Shuning Huang,
Adnan Bibic,
Jelena Mihailovic,
Andreia Morais,
Jessica Lamb,
Karisma Nagarkatti,
Marcio A. Dinitz,
Andre Rogatko,
Arthur W. Toga,
Patrick Lyden,
Cenk Ayata,
Ryan P. Cabeen
Abstract:
Rodent stroke models are important for evaluating treatments and understanding the pathophysiology and behavioral changes of brain ischemia, and magnetic resonance imaging (MRI) is a valuable tool for measuring outcome in preclinical studies. Brain extraction is an essential first step in most neuroimaging pipelines; however, it can be challenging in the presence of severe pathology and when datas…
▽ More
Rodent stroke models are important for evaluating treatments and understanding the pathophysiology and behavioral changes of brain ischemia, and magnetic resonance imaging (MRI) is a valuable tool for measuring outcome in preclinical studies. Brain extraction is an essential first step in most neuroimaging pipelines; however, it can be challenging in the presence of severe pathology and when dataset quality is highly variable. Convolutional neural networks (CNNs) can improve accuracy and reduce operator time, facilitating high throughput preclinical studies. As part of an ongoing preclinical stroke imaging study, we developed a deep-learning mouse brain extraction tool by using a U-net CNN. While previous studies have evaluated U-net architectures, we sought to evaluate their practical performance across data types. We ask how performance is affected with data across: six imaging centers, two time points after experimental stroke, and across four MRI contrasts. We trained, validated, and tested a typical U-net model on 240 multimodal MRI datasets including quantitative multi-echo T2 and apparent diffusivity coefficient (ADC) maps, and performed qualitative evaluation with a large preclinical stroke database (N=1,368). We describe the design and development of this system, and report our findings linking data characteristics to segmentation performance. We consistently found high accuracy and ability of the U-net architecture to generalize performance in a range of 95-97% accuracy, with only modest reductions in performance based on lower fidelity imaging hardware and brain pathology. This work can help inform the design of future preclinical rodent imaging studies and improve their scalability and reliability.
△ Less
Submitted 10 March, 2022;
originally announced March 2022.
-
Visualizing adverse events in clinical trials using correspondence analysis with R-package visae
Authors:
Márcio A. Diniz,
Gillian Gresham,
Sung** Kim,
Michael Luu,
N. Lynn Henry,
Mourad Tighiouart,
Greg Yothers,
Patricia A. Ganz,
André Rogatko
Abstract:
We propose to apply stacked CA using contribution biplots as a tool to explore differences in AE data among treatments in clinical trials. We defined five levels of refinement for the analysis based on data derived from the Common Terminology Criteria for Adverse Events (CTCAE) grades, domains, terms and their combinations. In addition, we developed a Shiny app built in an R-package, publicly avai…
▽ More
We propose to apply stacked CA using contribution biplots as a tool to explore differences in AE data among treatments in clinical trials. We defined five levels of refinement for the analysis based on data derived from the Common Terminology Criteria for Adverse Events (CTCAE) grades, domains, terms and their combinations. In addition, we developed a Shiny app built in an R-package, publicly available on Comprehensive R Archive Network (CRAN), to interactively investigate CA configurations. Data from two randomized controlled trials (RCT) were used to illustrate the proposed methods: NSABP R-04, a neoadjuvant rectal 2x2 factorial trial comparing radiation therapy with either capecitabine (Cape) or 5-fluorouracil (5-FU) alone with or without oxaliplatin (Oxa), and NSABP B-35, a double-blind RCT comparing tamoxifen to anastrozole in postmenopausal women with hormone-positive ductal carcinoma in situ. In the R04 trial (n=1308), CA biplots displayed the discrepancies between single agent treatments and their combinations with Oxa at all levels of AE classes, such that these discrepancies were responsible for the largest portion of the explained variability among treatments. In addition, an interaction effect when adding Oxa to Cape/5-FU was identified when the distance between Cape+Oxa and 5-FU+Oxa was observed to be larger than the distance between 5-FU and Cape, with Cape+Oxa and 5-FU+Oxa in different quadrants of the CA biplots. In the B35 trial (n=3009), CA biplots showed different patterns for non-adherent Anastrozole and Tamoxifen compared with their adherent counterparts. CA with contribution biplot is an effective tool that can be used to summarize AE data in a two-dimensional display while minimizing the loss of information and interpretation.
△ Less
Submitted 3 August, 2021; v1 submitted 9 January, 2021;
originally announced January 2021.
-
Comparison between continuous and discrete doses using Escalation With Overdose Control
Authors:
Márcio Augusto Diniz,
Mourad Tighiouart,
André Rogatko
Abstract:
Although there is an extensive statistical literature showing the disadvantages of discretizing continuous variables, categorization is a common practice in clinical research which results in substantial loss of information. A large collection of methods in cancer phase I clinical trial design establishes dose of a new agent as a discrete variable. A noteworthy exception is the Escalation With Ove…
▽ More
Although there is an extensive statistical literature showing the disadvantages of discretizing continuous variables, categorization is a common practice in clinical research which results in substantial loss of information. A large collection of methods in cancer phase I clinical trial design establishes dose of a new agent as a discrete variable. A noteworthy exception is the Escalation With Overdose Control (EWOC) design, where doses can be defined either as continuous or as a grid of discrete doses. A Monte Carlo simulation study was performed to compare the operating characteristics of continuous and discrete dose EWOC designs. Four equally spaced grids with different interval lengths were considered. The loss of information was measured by several operating characteristics easier for clinicians to interpret, in addition to the usual statistical measures of bias and mean squared error. Based on the simulations, if there is not enough knowledge about the true MTD value as commonly happens in phase I clinical trials, continuous dose scheme arises as an attractive option.
△ Less
Submitted 16 August, 2017;
originally announced August 2017.
-
Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials
Authors:
Mourad Tighiouart,
André Rogatko
Abstract:
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major endpoint in phase II and III trials is treatment efficacy. The dose sought is typically referred to as the maximum tolerated dose (MTD). Several statistical methodologies have been proposed to select the MTD in cancer phase I trials. In this manuscript, we focus on a Bayesia…
▽ More
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major endpoint in phase II and III trials is treatment efficacy. The dose sought is typically referred to as the maximum tolerated dose (MTD). Several statistical methodologies have been proposed to select the MTD in cancer phase I trials. In this manuscript, we focus on a Bayesian adaptive design, known as escalation with overdose control (EWOC). Several aspects of this design are discussed, including large sample properties of the sequence of doses selected in the trial, choice of prior distributions, and use of covariates. The methodology is exemplified with real-life examples of cancer phase I trials. In particular, we show in the recently completed ABR-217620 (naptumomab estafenatox) trial that omitting an important predictor of toxicity when dose assignments to cancer patients are determined results in a high percent of patients experiencing severe side effects and a significant proportion treated at sub-optimal doses.
△ Less
Submitted 30 November, 2010;
originally announced November 2010.
-
Neutrosophic Relational Data Model
Authors:
Haibin Wang,
Rajshekhar Sunderraman,
Florentin Smarandache,
Andre Rogatko
Abstract:
In this paper, we present a generalization of the relational data model based on interval neutrosophic set. Our data model is capable of manipulating incomplete as well as inconsistent information. Fuzzy relation or intuitionistic fuzzy relation can only handle incomplete information. Associated with each relation are two membership functions one is called truth-membership function T which keeps…
▽ More
In this paper, we present a generalization of the relational data model based on interval neutrosophic set. Our data model is capable of manipulating incomplete as well as inconsistent information. Fuzzy relation or intuitionistic fuzzy relation can only handle incomplete information. Associated with each relation are two membership functions one is called truth-membership function T which keeps track of the extent to which we believe the tuple is in the relation, another is called falsity-membership function F which keeps track of the extent to which we believe that it is not in the relation. A neutrosophic relation is inconsistent if there exists one tuple a such that T(a) + F(a) > 1 . In order to handle inconsistent situation, we propose an operator called "split" to transform inconsistent neutrosophic relations into pseudo-consistent neutrosophic relations and do the set-theoretic and relation-theoretic operations on them and finally use another operator called "combine" to transform the result back to neutrosophic relation. For this data model, we define algebraic operators that are generalizations of the usual operators such as intersection, union, selection, join on fuzzy relations. Our data model can underlie any database and knowledge-base management system that deals with incomplete and inconsistent information.
△ Less
Submitted 29 October, 2007;
originally announced October 2007.
-
A Neutrosophic Description Logic
Authors:
Haibin Wang,
Andre Rogatko,
Florentin Smarandache,
Rajshekhar Sunderraman
Abstract:
Description Logics (DLs) are appropriate, widely used, logics for managing structured knowledge. They allow reasoning about individuals and concepts, i.e. set of individuals with common properties. Typically, DLs are limited to dealing with crisp, well defined concepts. That is, concepts for which the problem whether an individual is an instance of it is yes/no question. More often than not, the…
▽ More
Description Logics (DLs) are appropriate, widely used, logics for managing structured knowledge. They allow reasoning about individuals and concepts, i.e. set of individuals with common properties. Typically, DLs are limited to dealing with crisp, well defined concepts. That is, concepts for which the problem whether an individual is an instance of it is yes/no question. More often than not, the concepts encountered in the real world do not have a precisely defined criteria of membership: we may say that an individual is an instance of a concept only to a certain degree, depending on the individual's properties. The DLs that deal with such fuzzy concepts are called fuzzy DLs. In order to deal with fuzzy, incomplete, indeterminate and inconsistent concepts, we need to extend the fuzzy DLs, combining the neutrosophic logic with a classical DL. In particular, concepts become neutrosophic (here neutrosophic means fuzzy, incomplete, indeterminate, and inconsistent), thus reasoning about neutrosophic concepts is supported. We'll define its syntax, its semantics, and describe its properties.
△ Less
Submitted 13 March, 2008; v1 submitted 22 November, 2006;
originally announced November 2006.
